Treating pulmonary hypertension in COPD: Where do we start?

European Respiratory Journal

Volumn 32, Issue 3, 2008, Pages 541-542

  Hoeper, M M ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; PLACEBO; POLYCYCLIC AROMATIC HYDROCARBON; SILDENAFIL; ANTIHYPERTENSIVE AGENT; SULFONAMIDE; VASODILATOR AGENT;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFECT; DRUG SAFETY; ECHOCARDIOGRAPHY; EDITORIAL; EXERCISE; HEART FAILURE; HEART OUTPUT; HEART VENTRICLE FUNCTION; HUMAN; LUNG ARTERY PRESSURE; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; SURVIVAL RATE; UNSPECIFIED SIDE EFFECT; NOTE; PATHOPHYSIOLOGY; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL;

ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION, PULMONARY; PILOT PROJECTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONAMIDES; VASODILATOR AGENTS;

EID: 58149376383     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00091908     Document Type: Editorial

References (18)

1. Dupuis J, Hoeper MM. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J 2008; 31: 407-414.
2. Olschewski H, Gomberg-Maitland M. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J 2008; 31: 801-901.
3. Wilkins MR, Wharton J, Grimminger F, Ghofrani HA. Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. Eur Respir J 2008; 32: 198-209.
4. Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in chronic obstructive pulmonary disease. Eur Respir J 2008; (In press).
5. Behr J, Ryu JH. Pulmonary hypertension in interstitial lung disease. Eur Respir J 2008; 31: 1357-1367.
6. Stolz D, Rasch H, Linka A, et al. A randomised, controlled trial of bosentan in severe COPD. Eur Respir J 2008; 32: 619-628.
7. Kessler R, Faller M, Weitzenblum E, et al. "Natural history" of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease. Am J Respir Crit Care Med 2001; 164: 219-224.
8. Rietema H, Holverda S, Bogaard HJ, et al. Sildenafil treatment in COPD does not affect stroke volume or exercise capacity. Eur Respir J 2008; 31: 759-764.
9. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004; 351: 1655-1665.
10. Santos S, Peinado VI, Ramirez J, et al. Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD. Eur Respir J 2002; 19: 632-638.
11. Weitzenblum E, Sautegeau A, Ehrhart M, Mammosser M, Hirth C, Roegel E. Long-term course of pulmonary arterial pressure in chronic obstructive pulmonary disease. Am Rev Respir Dis 1984; 130: 993-998.
12. Scharf SM, Iqbal M, Keller C, Criner G, Lee S, Fessler HE. Hemodynamic characterization of patients with severe emphysema. Am J Respir Crit Care Med 2002; 166: 314-322.
13. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358: 1119-1123.
14. Provencher S, Hervé P, Sitbon O, Humbert M, Simonneau G, Chemla D. Changes in exercise haemodynamics during treatment in pulmonary arterial hypertension. Eur Respir J 2008; [Epub ahead of print PMID: 18417516].
15. Simonneau G, Escourrou P, Duroux P, Lockhart A. Inhibition of hypoxic pulmonary vasoconstriction by nifedipine. N Engl J Med 1981; 304: 1582-1585.
16. Chaouat A, Bugnet AS, Kadaoui N, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172: 189-194.
17. Fisher MR, Criner GJ, Fishman AP, et al. Estimating pulmonary artery pressures by echocardiography in patients with emphysema. Eur Respir J 2007; 30: 914-921.
18. Arcasoy SM, Christie JD, Ferrari VA, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003; 167: 735-740.